Allogene Therapeutics has dropped the bulk of a cell therapy collaboration with Notch Therapeutics, leaving just one chimeric antigen receptor (CAR) target from the original deal. Allogene tapped the ...

Four Core Programs Leverage Unique Attributes in Product Development and Trial Design to Demonstrate the Unmatched Potential of an Allogeneic CAR T “Until now, CAR T development has been defined by ...

Allogene Therapeutics, Inc. (ALLO) has been able to advance a few CAR-T products in its pipeline. The reason why I believe that it is good to focus on this biotech next is because it is gearing up to ...

Allogene Therapeutics is a clinical-stage biotech developing allogeneic CAR T therapies for cancer and autoimmune diseases, with a focus on Cema-cel for LBCL. ALLO's advanced gene-editing platforms, ...

Long Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrate Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous Therapies Presentation ...

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T ...

On June 1, Allogene Therapeutics Inc. (NASDAQ:ALLO) presented updated data from the Phase 1 TRAVERSE study of ALLO-316 in advanced or metastatic renal cell carcinoma/RCC during an oral presentation at ...

Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in lymphoma show the therapy can “leapfrog” the competition. The biotech had been ...

Comprehensive Review of All Patients in the Phase 1 ALPHA/ALPHA2 Trials Demonstrate that Adding Investigational ALLO-647 to Standard Lymphodepletion Can Yield Durable Responses and a Safety Profile ...

Detailed price information for Allogene Therapeutics Inc (ALLO-Q) from The Globe and Mail including charting and trades.

Earlier today, Allogene and Pfizer announced that the two companies have entered into an asset contribution agreement for Pfizer’s allogeneic CAR T-cell therapy portfolio, which includes 16 ...